|
COPYRIGHT 2006 Voxant, Inc.
Original Source: CNBC/DOW JONES BUSINESS VIDEO
JOE KERNEN, CNBC ANCHOR: Endo Pharmaceuticals under some pressure this week after Bear Stearns said it needs to boost the prescriptions of its drug Opana in order -- is that -- is it Opana, Becky, do you know?
BECKY QUICK, CNBC ANCHOR: Crickets.
KERNEN: Just say -- yes, crickets. Ordered to meet for two -- we are going to have the CEO on. It has been a volatile year for Endo. It has been on a downswing since October. So what is the company doing to turn things around? Here to discuss the business is the CEO of Endo Pharma, Peter Lankau.
Good morning, sir. Good to see you.
PETER LANKAU, PRES. & CEO, ENDO PHARMACEUTICALS: Good morning. How are you?
KERNEN: I am well, thank you. Opana, Opana?
LANKAU: Opana.
KERNEN: Opana. The launch didn`t go as well as expected. How are sales now and how important is that to Endo?
LANKAU: Well, this is...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
